Back
Neurocrine Biosciences, Inc. 10K Form
Sell
50
NBIX
Neurocrine Biosciences, Inc.
Last Price:
$131.57
Seasonality Move:
9.25%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-01 | 10Q | NBIX/Neurocrine Biosciences, Inc. Quarterly |
| 2023-10-31 | 10Q | NBIX/Neurocrine Biosciences, Inc. Quarterly |
| 2023-08-01 | 10Q | NBIX/Neurocrine Biosciences, Inc. Quarterly |
| 2023-05-03 | 10Q | NBIX/Neurocrine Biosciences, Inc. Quarterly |
| 2022-11-01 | 10Q | NBIX/Neurocrine Biosciences, Inc. Quarterly |
| 2022-08-04 | 10Q | NBIX/Neurocrine Biosciences, Inc. Quarterly |
Receive NBIX News And Ratings
See the #1 stock for the next 7 days that we like better than NBIX
NBIX Financial Statistics
Sales & Book Value
| Annual Sales: | $2.9B |
|---|---|
| Cash Flow: | $390.8M |
| Price / Cash Flow: | 18 |
| Annual Sales: | $32.50 |
| Price / Book: | 4.06 |
Profitability
| EPS (TTM): | 4.66760 |
|---|---|
| Net Income (TTM): | $478.6M |
| Gross Margin: | $2.8B |
| Return on Equity: | 17% |
| Return on Assets: | 11.71% |
Neurocrine Biosciences, Inc. Earnings Forecast
Key Neurocrine Biosciences, Inc. Financial Ratios
-
The Gross Profit Margin over the past 30 years for NBIX is 98.18%.
-
The Selling, General & Administrative Expenses for NBIX have been equal to 40.42% of Gross Profit Margin.
-
The Research & Development expenses have been 35.51% of Revenue.
-
The Interest Expense is 0.00% of Operating Income.
-
The Net Earning history of NBIX is 16.73% of Total Revenues.
-
Per Share Earnings over the last 30 years have been positive in 16 years.
Neurocrine Biosciences, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | NBIX |
| CUSIP: | 64125C |
| Website: | neurocrine.com |
Debt
| Debt-to-Equity Ratio: | 0.14 |
|---|---|
| Current Ratio: | 3.39 |
| Quick Ratio: | 2.92 |
Price-to-Earnings
| Trailing P/E Ratio: | 28.18 |
|---|---|
| Forward P/E Ratio: | 13.54 |
NBIX Technical Analysis vs Fundamental Analysis
Sell
50
Neurocrine Biosciences, Inc. (NBIX)
is a Sell
Is Neurocrine Biosciences, Inc. a Buy or a Sell?
-
Neurocrine Biosciences, Inc. stock is rated a SellThe current Neurocrine Biosciences, Inc. [NBIX] share price is $131.60. The Score for NBIX is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.